Download PDF

下载PDF

CAMBRIDGE, Mass., April 01, 2025 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that Phase 1 dose escalation and backfill cohort clinical data for emiltatug ledadotin (Emi-Le; XMT-1660) will be presented in an oral session at the ESMO Breast Cancer 2025 Annual Congress, which is being held from May 14-17, 2025, in Munich, Germany..

马萨诸塞州剑桥，2025年4月1日（环球新闻社）——Mersana Therapeutics, Inc.（纳斯达克股票代码：MRSN），一家专注于发现和开发针对高未满足医疗需求领域癌症的抗体药物偶联物（ADC）管线的临床阶段生物制药公司，今天宣布，emiltatug ledadotin（Emi-Le；XMT-1660）的1期剂量递增和回填队列临床数据将在2025年5月14日至17日在德国慕尼黑举行的ESMO乳腺癌2025年年度大会上以口头报告形式展示。

Oral Presentation Details

口头报告详情

Title:

标题：

Clinical Activity of Emiltatug Ledadotin (Emi-Le), a B7-H4-Directed ADC, in Patients with TNBC who Received at Least One Prior Topoisomerase-1 Inhibitor (Topo-1) ADC

B7-H4导向的ADC药物Emiltatug Ledadotin（Emi-Le）在至少接受过一种拓扑异构酶-1抑制剂（Topo-1）ADC治疗的三阴性乳腺癌（TNBC）患者中的临床活性

Session Title:

会话标题：

Mini Oral Session 1

小型口头报告会议 1

Date and Time:

日期和时间：

Thursday, May 15, 2025 from 8:30-10:00 a.m. CEST

2025年5月15日星期四，欧洲中部夏令时间上午8:30-10:00

Abstract Number:

摘要编号：

298MO

298MO

Presenter:

主持人：

Erika Hamilton, M.D., Director Breast Cancer Research, Sarah Cannon Research Institute in Nashville, Tennessee

田纳西州纳什维尔市莎拉·坎农研究所乳腺癌研究主任，艾丽卡·汉密尔顿医学博士

About

关于

Emi-Le

埃米-勒

Emi-Le is a B7-H4-directed Dolasynthen ADC with a precise, target-optimized drug-to-antibody ratio (DAR 6) and a proprietary auristatin payload with controlled bystander effect. This candidate is being investigated in a Phase 1 dose escalation and expansion trial in patients with solid tumors, including breast, endometrial and ovarian cancers as well as adenoid cystic carcinoma type 1.

Emi-Le 是一种针对 B7-H4 的 Dolasynthen 抗体药物偶联物 (ADC)，具有精确的、针对靶点优化的药物抗体比 (DAR 6)，以及一种具有可控旁观者效应的专有 auristatin 毒性载荷。该候选药物正在一项 I 期剂量递增和扩展试验中进行研究，适用于包括乳腺癌、子宫内膜癌、卵巢癌以及 1 型腺样囊性癌在内的实体瘤患者。

In the initial clinical data that were reported as of a December 13, 2024 data cutoff, Emi-Le was observed to be generally well tolerated with differentiated safety and tolerability profile. Additionally, confirmed objective responses were observed across all enrolled tumor types, including in patients with triple negative breast cancer (TNBC) who had previously been treated with a topoisomerase-1 inhibitor (topo-1) ADC..

在截至2024年12月13日的初步临床数据中，Emi-Le总体上显示出良好的耐受性，具有独特的安全性和耐受性特征。此外，在所有入组的肿瘤类型中均观察到确认的客观缓解，包括既往接受过拓扑异构酶1抑制剂（topo-1）ADC治疗的三阴性乳腺癌（TNBC）患者。

The U.S. Food and Drug Administration has granted two Fast Track designations to Emi-Le for the treatment of 1) adult patients with advanced or metastatic triple-negative breast cancer, and 2) advanced or metastatic breast cancer in patients with human epidermal growth factor receptor 2 (HER2) low (IHC 1+ or IHC 2+/ISH–) or HER2-negative (IHC 0) disease, including TNBC, who have received a prior topo-1 ADC.

美国食品药品监督管理局（FDA）已授予Emi-Le两项快速通道资格，用于治疗：1) 晚期或转移性三阴性乳腺癌的成年患者；2) 人类表皮生长因子受体2（HER2）低表达（IHC 1+ 或 IHC 2+/ISH–）或HER2阴性（IHC 0）的晚期或转移性乳腺癌患者，包括曾接受过拓扑异构酶1抗体药物偶联物（topo-1 ADC）治疗的三阴性乳腺癌（TNBC）。

For more information about Mersana’s ongoing Phase 1 trial of Emi-Le, please visit clinicaltrials.gov (NCT05377996)..

有关Mersana正在进行的Emi-Le一期试验的更多信息，请访问clinicaltrials.gov（NCT05377996）。

About Mersana Therapeutics

关于Mersana Therapeutics

Mersana Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel antibody-drug conjugates (ADCs) and driven by the knowledge that patients are waiting for new treatment options. The company has developed proprietary cytotoxic (Dolasynthen) and immunostimulatory (Immunosynthen) ADC platforms that are generating a pipeline of wholly-owned and partnered product candidates with the potential to treat a range of cancers.

迈尔斯纳治疗公司是一家临床阶段的生物制药公司，专注于开发新型抗体药物偶联物（ADC），并深知患者正在等待新的治疗选择。该公司已开发出专有的细胞毒性（Dolasynthen）和免疫刺激（Immunosynthen）ADC平台，这些平台正在生成一条完全拥有和合作候选产品的管线，有潜力治疗多种癌症。

Its pipeline includes Emi-Le (emiltatug ledadotin; XMT-1660), a Dolasynthen ADC targeting B7-H4, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). Mersana routinely posts information that may be useful to investors on the “Investors & Media” section of its website at .

其产品线包括Emi-Le（emiltatug ledadotin；XMT-1660），一种靶向B7-H4的Dolasynthen抗体药物偶联物（ADC），以及XMT-2056，一种靶向人类表皮生长因子受体2（HER2）新表位的Immunosynthen抗体药物偶联物（ADC）。Mersana经常在其网站的“投资者与媒体”部分发布可能对投资者有用的信息。

www.mersana.com

www.mersana.com

.

。

Contact:

联系人：

Jason Fredette

杰森·弗雷德特

617-498-0020

617-498-0020

jason.fredette@mersana.com

杰森·弗雷德特@mersana.com